Abstract
One potential mechanism for protection from SARS-CoV-2 in infants and young children is through passive immunity via breast milk from a mother previously infected with the novel coronavirus. The primary objectives of this study were to establish the presence of SARS-CoV-2 specific IgA and IgG and to characterize the specific antigenic regions of SARS-CoV-2 proteins that were reactive with antibodies in breast milk from women with confirmed SARS-CoV-2 infection.
Between March 2020 and September 2020, 21 women with confirmed SARS-CoV-2 infection were enrolled into Mommy’s Milk at the University of California, San Diego. Women donated serial breast milk samples. Breast milk samples were used to probe a multi-coronavirus protein microarray containing full-length proteins and variable length overlapping fragments of SARS-CoV-2 spike (S), envelope (E), membrane (M), nucleocapsid (N), and open reading frame (ORF) proteins.
The breast milk samples contained IgA reactive with a variety of SARS-CoV-2 antigens. The most IgA-reactive SARS-CoV-2 proteins were N (42.9% of women responded to 1 ≥ N fragment) and S proteins (23.9% of women responded to ≥ 1 fragment of S1 or S2). Overall, individual COVID-19 cases had diverse and unique milk IgA profiles over the course of follow-up since onset of SARS-CoV-2 symptoms.
Competing Interest Statement
Dr. Bode reported serving as the UC San Diego Chair of Collaborative Human Milk Research, endowed by the Family Larsson-Rosenquist Foundation, which also provided emergency funding for this project. Medela Corporation provided milk sample collection materials for this study. Dr. Chambers reports that shipping of milk samples was financially supported by the Mothers Milk Bank at Austin, an accredited milk bank and member of the Human Milk Banking Association of North American, and support for banking of samples in the Mommys Milk Human Milk Biorepository at UC San Diego was provided by National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) under Award Number UL1TR001442 to Gary Firestein at UC San Diego Altman Clinical Translational Research Institute (ACTRI). David Camerini and Joseph J. Campo are employees of Antigen Discovery Inc. The other authors have no relevant conflicts to disclose.
Funding Statement
Dr. Bode reported serving as the UC San Diego Chair of Collaborative Human Milk Research, endowed by the Family Larsson-Rosenquist Foundation, which also provided emergency funding for this project. Medela Corporation provided milk sample collection materials for this study. Dr. Chambers reports that shipping of milk samples was financially supported by the Mothers Milk Bank at Austin, an accredited milk bank and member of the Human Milk Banking Association of North American, and support for banking of samples in the Mommys Milk Human Milk Biorepository at UC San Diego was provided by National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) under Award Number UL1TR001442 to Gary Firestein at UC San Diego Altman Clinical Translational Research Institute (ACTRI). David Camerini and Joseph J. Campo are employees of Antigen Discovery Inc. The other authors have no relevant conflicts to disclose.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The University of California San Diego Institutional Review Board approved the study, and women provided oral and written informed consent prior to use of their breast milk samples in the analyses described above.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data access may be provided, with appropriate ethics approval, by contacting the authors.
